While Qiagen NV (NASDAQ:QGEN) isn’t scheduled to report their 2015 year-end results until February 2, investors have received a preview of those results, and they are not good. The company has warned that they will miss their own expectations for 2015. While they had originally predicted an EPS of $1.16, the company now warns shareholder that their 2015 EPS will be around $1.13 to $1.14. Additionally, Qiagen NV (NASDAQ:QGEN) has lowered their 2015 constant currency sales growth from 4% to 3% on volatile timing of sales.
“This performance was hampered by factors that included volatility in the timing of revenues from the growing portfolio of companion diagnostic partnerships as well as lower revenues from instruments,” Chief Executive Peer M. Schatz said in a statement.
Shares of Qiagen NV (NASDAQ:QGEN) are trading significantly lower in the early morning today, the lowest they have been since last February. The stock has fallen 10.11% or $2.58 following this negative news, hitting $22.99 per share. Approximately 439,820 shares traded hands. QGEN shares have risen 5.01% since June 5, 2015 and are currently uptrending. It has outperformed the S&P500 by 9.70%.
From a total of 7 analysts covering Qiagen (NASDAQ:QGEN) stock, 3 rate it a “Buy”, 0 a “Sell”, and 4 a “Hold”. This means that 43% of the ratings are positive. The highest target price is $33 while the lowest target price is $20. The mean of all analyst targets is $28 which is 21.79% above today’s ($22.99) stock price. Qiagen was the topic of 7 analyst reports since August 3, 2015 according to the firm StockzIntelligence Inc. Stifel Nicolaus initiated shares on November 12 with a “Hold” rating. Barclays Capital maintained QGEN stock in a recent report from July 30 with a “Overweight” rating.
QIAGEN N.V. is a Netherlands holding company. The company has a market cap of $5.51 billion. The Firm and its subsidiaries are engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. It has 52.44 P/E ratio. Sample to Insight solutions are composed of sample and assay technologies, bioinformatics and automation systems.